

Publikationer 2003-2016

2016-06-01

2016

Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A. A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.

Multiple Sclerosis, April 2016, 1-9

2015

Hillert J, Stawiarz L. The Swedish MS registry – clinical support tool and scientific resource.

Acta Neurol Scand Suppl. 2015;132(199):11-19.

Goris, A., et al., Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Brain, 2015. 138(Pt 3): p. 632-43.

Hedström AK, Åkerstedt T, Olsson T, Alfredsson L. Shift work influences multiple sclerosis risk.

Mult Scler. 2015 Aug;21(9):1195-9.

Hedström AK, Lima Bomfim I, Hillert J, et al. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis.

Eur J Neurol. 2015 Mar;22(3):578.

Kavaliunas A, Stawiarz L, Hedbom J, Hillert J, et al. The influence of immunomodulatory treatment on the clinical course of multiple sclerosis.

Adv Exp Med Biol. 2015;822:19-24.

Boström I, Landtblom AM. Does the changing sex ratio of multiple sclerosis give opportunities for intervention?

Acta Neurol Scand 2015; 132 (suppl. 199).

Matell Henrik, Lycke Jan, Piehl Fredrik, et al. Age-dependent effects on the treatment response of natalizumab in MS patients.

Mult Scler 2015. 21(1): p. 48-56.

Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined hormonal contraception (patienterna rekryterats via registret men inga data ur registret använts).

Eur J Obstet Gynecol Reprod Biol; October 2015, Vol.193, pp.1-4.

Ramanujam R, Hedström A-K, Hillert J et al. Effect of Smoking Cessation on Multiple Sclerosis Prognosis.

JAMA Neurology, 1 October 2015, Vol.72(10), pp.1117-23

Roshanifefat, H., et al., All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population-based cohort study.

European Journal of Neurology, 2015. 22(7): p. 1074-80.

Salzer J, Lycke J, Svenningsson A et al. Rituximab in paediatric onset multiple sclerosis: a case series.

Journal of Neurology. 2015;263:322-326

Sundal, Christina; Baker, Michelle; Andersen, Oluf et al. Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis.

European Journal of Neurology 2015;22:328-333.

Svenningsson A, Salzer J, Svenningsson A et al. Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden.

Acta Neurologica Scandinavica, 2015, Vol.132(6), pp.389-394

Tedeholm H, Skoog B, Andersen O et al. The outcome spectrum of multiple sclerosis: Disability, mortality, and a cluster of predictors from onset.
Journal of Neurology 2015; 262:1148-1163.

Westerlind H, Imrell K, Hillert J et al. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort.
Eur J Hum Genet. 2015 May;23(5):688-92.

Wiberg, Michael, Friberg, Emilie, Tinghög, Petter et al. Sources and level of income among individuals with multiple sclerosis compared to the general population: A nationwide population-based study.
Multiple Sclerosis 2015, Vol.21(13), pp.1730-1741

Wickström A, Sundström P, Svenningsson A et al. Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.
Mult Scler Journal – ETC 2015, 1:1-9

Kavaliunas A, Wiberg M, Tinghog P, Hillert J et al. Earnings and financial compensation from social security systems correlate strongly with disability for multiple sclerosis patients.(Report)
PLoS ONE, Dec 22, 2015, Vol.10(12)

Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Int Multiple Sclerosis Genetics Consortium et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.
Brain. 2015 Mar;138(Pt 3):632-43.

2014

Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Spulber G, Wahlund LO, Hillert J, Westman E, Karrenbauer VD. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy.
J Neuroimmunol. 2014 Sep 15;274(1-2):149-54.

Wickström A, Dahle C, Svenningsson A et al. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
Multiple Sclerosis Journal, 2014, Vol.20(8), pp.1095-1101

Stawiarz L, Hagel E, Eriksson H, Hillert J and Swedish MS Registry. A Visualization and Analysis Platform in the Swedish National MS Registry for Real-Time Data Feedback (conference paper P216)
Joint ACTRIMS-ECTRIMS Meeting 10-13 September 2014, Boston, Massachusetts USA

Jonsson L, Holmén C, Hillert J, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Landtblom A-M, Burman J, Walentin F, Martin C, Piehl F, Olsson T. A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of Natalizumab (conference paper P221)
Joint ACTRIMS-ECTRIMS Meeting 10-13 September 2014, Boston, Massachusetts USA

Kavaliunas A, Stawiarz L, Glaser A, Hillert J. The influence of immunomodulatory treatment on the clinical course of Multiple Sclerosis (conference paper P281)
Joint ACTRIMS-ECTRIMS Meeting 10-13 September 2014, Boston, Massachusetts USA

Frisell T, Jonsson L, Nordin N, Holmén C, Askling J, Hillert J, Piehl, Olsson T. Comparative analysis of drop-out rates during the first year of fingolimod versus natalizumab treatment in the Swedish IMSE registry (conference paper P314)
Joint ACTRIMS-ECTRIMS Meeting 10-13 September 2014, Boston, Massachusetts USA

Ueda P, Rafatnia F, Bäärnhelm M, Fröbom R, Korzunowicz G, Lönnerbro R, Hedström AK, Eyles D, Olsson T, Alfredsson L. Neonatal vitamin D status and risk of multiple sclerosis.
Ann Neurol. 2014 Sep;76(3):338-46.

Westerlind H, Imrell K, Ramanujam R, Myhr KM, Celius EG, Harbo HF, Oturai AB, Hamsten A, Alfredsson L, Olsson T, Kockum I, Koski T, Hillert J. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. *Eur J Hum Genet.* 2014 Aug 27 [Epub ahead of print]

Gustavsen MW, Viken MK, Celius EG, Berge T, Mero IL, Berg-Hansen P, Aarseth JH, Myhr KM, Søndergaard HB, Sellebjerg F, Oturai AB, Hillert J, Alfredsson L, Olsson T, Kockum I, Lie BA, Harbo HF. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. *J Neuroimmunol.* 2014 Jul 6. [Epub ahead of print].

Engdahl E, Gustafsson R, Ramanujam R, Sundqvist E, Olsson T, Hillert J, Alfredsson L, Kockum I, Fogdell-Hahn A. HLA-A*02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6. *Hum Immunol.* 2014 Jun;75(6):524-30.

Westerlind H, Boström I, Stawiarz L, Landtblom AM, Almqvist C, Hillert J. New data identify an increasing sex ratio of multiple sclerosis in Sweden. *Mult Scler.* 2014 May 19. Epub ahead of print

Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. *Mult Scler.* 2014 May;20(6):726-32.

Gyllenberg A, Piehl F, Alfredsson L, Hillert J, Bomfim IL, Padyukov L, Orho-Melander M, Lindholm E, Landin-Olsson M, Lernmark A; The Swedish Childhood Diabetes Study Group, Aili M, Bååth LE, Carlsson E, Edenwall H, Forsander G, Granström BW, Gustavsson I, Hanas R, Hellenberg L, Hellgren H, Holmberg E, Hörnell H, Ivarsson SA, Johansson C, Jonsell G, Kockum K, Lindblad B, Lindh A, Ludvigsson J, Myrdal U, Neiderud J, Segnestam K, Sjö S, Skogsberg L, Strömberg L, Ståhle U, Thalme B, Tullus K, Tuvemo T, Wallensteen M, Westphal O, Aman J; The Diabetes Incidence in Sweden Study Group, Arnqvist H, Björck E, Eriksson J, Nyström L, Ohlson LO, Scherstén B, Ostman J, Olsson T, Kockum I. Variability in the CIITA gene interacts with HLA in multiple sclerosis. *Genes Immun.* 2014 Apr-May;15(3):162-7.

Boström I, Stawiarz L, Landtblom AM. Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). *Mult Scler.* 2014 Apr;20(4):513-4.

Hedström A, Hillert J, Olsson T, Alfredsson L. Reverse causality behind the association between reproductive history and MS. *Mult Scler.* 2014 Apr;20(4):406-11

Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Søndergaard HB, Hillert J; International Multiple Sclerosis Genetics Consortium, Oturai AB, Hemme B, Kockum I, Olsson T. JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants. *PLoS Pathog.* 2014 Apr 24;10(4)

Hedström AK, Ryner M; Fink K, Fogdell Hahn A, Alfredsson L, Olsson T, Jan Hillert J. Smoking and risk of treatment-induced neutralizing antibodies to interferon β -1a. *Mult Scler.* 2014 Apr;20(4):445-50

Landtblom AM. MS-tailored and specific documentation systems: do we need them?" (in session: E-documentation systems)
ECTRIMS workshop Lissabon 20140306

Westerlind H, Ramanujam R, Uvehag D, Kuja-Halkola R, Boman M, Bottai M, Lichtenstein P, Hillert J. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. *Brain.* 2014 Mar;137(Pt 3):770-8

Hedström AK, Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, Olsson T, Alfredsson L. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. *Neurology*. 2014 Mar 11;82(10):865-72

Hedström AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. *JAMA Neurol*. 2014 Mar;71(3):300-5.

Sundqvist E, Bergström T, Daialhosein H, Nyström M, Sundström P, Hillert J, Alfredsson L, Kockum I, Olsson T. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. *Mult Scler*. 2014 Feb;20(2):165-73.

Per Kempe. Multiple Sclerosis in relation to sex steroid exposure.

Doktorsavhandling på Division of Obstetrics and Gynaecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden, 2014-09-11.

Linköping University Medical Dissertations No. 1415, ISBN 978-91-7519-257-4, handledare: prof. Jan Brynhildsen, bi-handledare: prof. Mats Hammar

2013

Hedström A, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T. Smokers run increased risk of developing anti-natalizumab antibodies. *Mult Scler*. 2013 Dec 5;20(8):1081-1085

Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis susceptibility. *Eur J Epidemiol*. 2013 Nov;28(11):867-74.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kempainen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermodé A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Maciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat Genet*. 2013 Nov;45(11):1353-60.

Wickström A, Nyström J, Svenningsson A. Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment. *Multiple Sclerosis*. 2013 Apr;19(5):622-30.

Boström I, Stawiarz L, Landtblom AM. Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). Letter to Editor, *Mult Scler*. 2013

Boström I, Stawiarz L, Landtblom AM. Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). *Mult Scler.* 2013 Jan;19(1):46-52

Hedström AK, Hillert J, Olsson T, Alfredsson L. Nicotine might have a protective effect in the etiology of multiple sclerosis. *Mult Scler.* 2013 Jul;19(8):1009-13

Flensner G, Landtblom AM, Söderhamn O, Ek AC. Work capacity and health-related quality of life among individuals with multiple sclerosis reduced by fatigue: a cross-sectional study. *BMC Public Health.* 2013 Mar 15;13:224

Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. *Mult Scler.* 2013 May;19(6):765-74

Hedström A, Hillert J, Olsson T, Alfredsson L. Exposure to anaesthetic agents does not affect MS risk. *Eur J Neurol.* 2013 May;20(5):735-9

Hedström A, Hillert J, Olsson T, Alfredsson L. Nicotine might have a preventive effect in the etiology of multiple sclerosis. *Mult Scler.* 2013 Jul;19(8):1009-13

G Bergendal, J Martola, L Stawiarz, M Kristoffersen-Wiberg, S Fredrikson, O Almkvist. Callosal atrophy in multiple sclerosis is related to cognitive speed. *Acta Neurologica Scandinavica,* 2013 Apr;127(4):281-9.

Mero IL, Gustavsen MW, Sather HS, Flåm ST, Søndergaard HB, Jensen PEH, Berge T, Bjölgerud A, Muggerud A, Aarseth JH, Myhr KM, Celius EG, Sellebjerg F, Hillert J, Alfredsson L, Olsson T, Oturai AB, Kockum I, Lie BA, Kulle B, Harbo HF. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. *Plos One PLoS One.* 2013;8(3)

Lundström W, Highfill S, Walsh STR, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mckall CL. Soluble IL7R α Potentiates IL-7 Bioactivity and Promotes Autoimmunity. *PNAS.* 2013 Apr 22

International Multiple Sclerosis Genetics Consortium (IMSGC), Sergio E. Baranzini, Pouya Khankhanian, Nikolaos A. Patsopoulos, Michael Li, Jim Stankovich, Chris Cotsapas, Helle Bach Søndergaard, Maria Ban, Nadia Barizzone, Laura Bergamaschi, David Booth, Dorothea Buck, Paola Cavalla, Elisabeth G. Celius, Manuel Comabella, Giancarlo Comi, Alastair Compston, Isabelle Courou-Rebeix, Sandra D'Alfonso, Vincent Damotte, Lennox Din, Bénédicte Dubois, Irina Elovaara, Federica Esposito, Bertrand Fontaine, Andre Franke, An Goris, Pierre-Antoine Gourraud, Christiane Graetz, Franca R. Guerini, Léna Guillot-Noel, David Hafler, Hakon Hakonarson, Per Hall, Anders Hamsten, Hanne F. Harbo, Bernhard Hemmer, Jan Hillert, Anu Kemppinen, Ingrid Kockum, Keijo Koivisto, Malin Larsson, Mark Lathrop, Maurizio Leone, Christina M. Lill, Fabio Maciardi, Roland Martin, Vittorio Martinelli, Filippo Martinelli-Boneschi, Jacob L. McCauley, Kjell-Morten Myhr, Paola Naldi, Tomas Olsson, Annette Oturai, Margaret A. Pericak-Vance, Franco Perla, Mauri Reunanen, Janna Saarela, Safa Saker-Delye, Marco Salvetti, Finn Sellebjerg, Per Soelberg Sørensen, Anne Spurkland, Graeme Stewart, Bruce Taylor, Pentti Tienari, Juliane Winkelmann, Wellcome Trust Case Control Consortium 2, Frauke Zipp, Adrian J. Iverson, Jonathan L. Haines, Stephen Sawcer, Philip DeJager, Stephen L. Hauser, and Jorge R. Oksenberg; Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. *Am J Hum Genet.* 2013 May 22.

Leone MA, Barizzone N, Esposito F, Lucenti A, Harbo HF, Goris A, Kockum I, Oturai AB, Celius EG, Mero IL, Dubois B, Olsson T, Søndergaard HB, Cusi D, Lupoli S, Andreassen BK; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Myhr KM, Guerini FR; PROGEMUS Group; PROGRESSO Group, Comi G,

Martinelli-Boneschi F, D'Alfonso S. Association of Genetic Markers with CSF Oligoclonal Bands in Multiple Sclerosis Patients.

PLoS One. 2013 Jun 13;8(6)

Tedeholm H, Skoog B, Runmarker B, Odén A, Andersen O: Factors determining the risk of conversion to secondary progressive multiple sclerosis.

Poster at the ECTRIMS Meeting 2013. Mult. Scler 2013;19:S1:358.

2012

Andersen O. From the Gothenburg cohort to the Swedish multiple sclerosis registry.

Acta Neurol Scand 2012;195:13-19.

Roshanifefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S. Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis.

Mult Scler. 2012 Oct;18(10):1430-6

Mellergård J, Tisell A, Dahlqvist Leinhard O, Blystad I, Landtblom AM, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P, Vrethem M. Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis.

PLoS One. 2012;7(9)

Sundquist E, Sundström P, Linden M, Hedström AK, Aloisi F, Hillert J, Kockum I, Alfredsson L, Olsson T. Lack of replication of interaction between EBNA1 IgGAb and smoking in the risk for multiples sclerosis.

Neurology, 2012 Sep 25;79(13):1363-8.

Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, Schaffer M, Alfredsson L, Olsson T, Brynedal B, Harbo HF, Hillert J. Importance of Human Leukocyte Antigen (HLA) class I and II Alleles on the Risk of Multiple Sclerosis.

Plos One 2012;7(5)

Malmeström C, Gillett A, Jernås M, Khademi M, Axelsson M, Kockum I, Mattsson N, Zetterberg H, Blennow K, Alfredsson L, Wadenvik H, Lycke J, Olsson T, Olsson B. Serum levels of LIGHT in multiple sclerosis.

Multiple Sclerosis Journal, on line 4 Oct 2012

Lindén M, Khademi M, Lima Bomfim I, Piehl F, Jagodic M, Kockum I, Olsson T. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.

Mult Scler. 2012 Nov 22

Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women.

Mult Scler. 2012 Sep;18(9):1334-6.

Ahlgren C, Odén A, Lycke J. A nationwide survey of the prevalence of multiple sclerosis in immigrant populations of Sweden.

Mult Scler. 2012 Aug;18(8):1099-107.

Karrenbauer VD, Prejs R, Masterman T, Hillert J, Glaser A, Imrell K. Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients.

J Neuroimmunol. 2012 Sep 8.

Bäärnhielm M, Hedström AK, Kockum I, Sundqvist E, Gustafsson S, Hillert J, Olsson T, Alfredsson L. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15

Eur J Neurol. 2012 Jul;19(7):955-62

Sundqvist E, Sundström P, Linden M, Hedström AK, Aloisi F, Hillert J, Alfredsson L, Kockum I, Olsson T, Epstein-Barr virus and multiple sclerosis: interaction with HLA.
Genes Immun. 2012 Jan;13(1):14-20.

Carolina Havervall, Department of Neurochemistry, Stockholm University and Centrum for Molecular Medicine (CMM), Karolinska Institutet. Biomarkers and Genetics in Multiple Sclerosis (MS) and MS-like disease.
Master Thesis in Neurogenetics, May 2012, handledare: Fredrik Piehl (KI), Mohsen Khademi (KI) and Kerstin Iverfeldt (SU)

Mahsa Fatahi, School of Technology and Health, Royal Institute of Technology (KTH) and Medical Imaging Laboratory (SMILE) at Karolinska University Hospital-Huddinge, Stockholm. Progression of Multiple Sclerosis related atrophy, evaluated by MRI-based volumetric method.
Master Thesis in Medical Imaging, Feb 2012, handledare: Leszek Stawiarz (KI), Eva Örndahl (KS)

Skoog B, Tedeholm H, Runmarker B, Odén A, Andersen O: A new method to identify multiple sclerosis with a high risk of secondary progression.
Poster at the ECTRIMS congress 2012. Mult Scler. 2012;18:S2;91.

Skoog B, Tedeholm H, Runmarker B, Odén A, Andersen O. A method to identify periods with a high risk of secondary progression in multiple sclerosis.
Short communication at the EFNS congress 2012. European J. Neurol. 2012;19, supplement 1:29.

Ahlgren Cecilia, Först nationella prevalensen av MS i Sverige
Neurologi, nr 2, 2012, sid 36-39.

Lycke Jan, MS prevalens i Sverige betydligt högre än förväntat
Best Practice nr 10 maj 2012, sid 16-19

2011

Lindén M, Nohra R, Sundqvist E, Khademi M, Hillert J, Alfredsson L, Olsson T, Kockum I. No evidence of IL21 association with multiple sclerosis in a Swedish population.
Tissue Antigens. 2011 Oct;78(4):271-4

Søndergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Lindén M, Mero IL, Myhr KM, Celius EG, Harbo HF, Christensen JR, Börnsen L, Sørensen PS, Oturai AB. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655.
Eur J Hum Genet. 2011 Oct;19(10):1100-3.

Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis.
Acta Neurol Scand 2011 Mar;123(3):207-10

Hedström AK, Sundqvist E, Bäärnhielm M, Hillert J, Kockum I, Olsson T, Alfredsson L. Smoking and two HLA genes interact to increase the risk for multiple sclerosis.
Brain 2011, 134, 653-664.

Piehl F, Holmen C, Hillert J, Olsson T. Swedish natalizumab (Tysabri) surveillance study.
Neurol Sci. 2011 Jan;31 Suppl 3:289-93

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulidou E, D'Alfonso S, Blackburn H, Boneschi FM, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kempainen A, Weston P, Hawkins C, Widaa S, Zajicek J,

Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermod AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macchiardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

Nature. 2011 Aug 10;476(7359):214-9

Gunnarsson M, Malmström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Axonal damage in multiple sclerosis is markedly reduced by natalizumab treatment.

Annals of Neurology, 2011, 69, 83-89.

Björkhem I, Lövgren-Sandblom A, Piehl F, Khademi M, Pettersson H, Leoni V, Olsson T, Diczfaluzi U. High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis. Facts or fiction.

J Lipid Res. 2011;52:170-4.

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Mult Scler. 2011;17, 335-343.

Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

Mult Scler. 2011, 17, 32-42.

Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundqvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Multiple Sclerosis, Jan 2011

Sundqvist E, Sundström P, Linden M, Hedström AK, Aloisi F, Hillert J, Alfredsson L, Kockum I, Olsson T, EBV, infectious mononucleosis and Multiple Sclerosis: association with disease and interaction with HLA.

Genes and Immunity, 2011 Jul 21.

Lindén M, Nohra R, Sundqvist E, Khademi M, Hillert J, Alfredsson L, Olsson T, Kockum I. No evidence of IL21 association with multiple sclerosis in a Swedish population.

Tissue Antigens. 2011 Jul 8

Søndergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Lindén M, Mero IL, Myhr KM, Celius EG, Harbo HF, Christensen JR, Börnsen L, Sørensen PS, Oturai AB. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655.

Eur J Hum Genet. 2011 May 25

Iacobaeus E, Amoudruz P, Ström M, Khademi M, Brundin L, Hillert J, Kockum I, Malmström V, Olsson T, Tham E, Piehl F. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.

PLoS One. 2011 May 6;6(5):e19138.

International Multiple Sclerosis Genetics Consortium. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.

PLoS One. 2011 Apr 28;6(4):e18813.

Hedström AK, Bäärnhielm M, Olsson T#, Alfredsson L#. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. *#equal contribution.*

Mult Scler. 2011 Jul;17(7):788-93

Hedström, AK, Åkerstedt T, Olsson T#, Alfredsson L# Shift work at young age is associated with increased risk for Multiple Sclerosis. *#equal contribution.*

Ann Neurol. 2011 Nov;70(5):733-41

Roshanifefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery SM. Appendectomy and multiple sclerosis risk.

Eur J Neurol. 2011 Apr;18(4):667-9

Virpi Leppä, Ida Surakka, Pentti J. Tienari, Irina Elovaara, Alastair Compston, Stephen Sawcer, Neil Robertson, Philip De Jager, Cristin Aubin, David A. Hafler, Annette Bang Oturai, Helle Bach Søndergaard, Finn Sellebjerg, Per Soelberg Sørensen, Bernhard Hemmer, Sabine Cepok, Juliane Winkelmann, Heinz-Erich Wichmann, Manuel Comabella, Marta Fernández, Xavier Montalban, Tomas Olsson, I Kockum, Jan Hillert, Lars Alfredsson, An Goris, Bénédicte Dubois, Inger-Lise Mero, Cathrine Smestad, Elisabeth G. Celius, Hanne F. Harbo, Sandra D'Alfonso, Laura Bergamaschi, Maurizio Leone, Giovanni Ristori, Ludwig Kappos, Stephen L Hauser, Isabelle Cournu-Rebeix, Bertrand Fontaine, Steven Boonen, Chris Polman, Aarno Palotie, Leena Peltonen, and Janna Saarela , The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: a Multicenter Case-Control Study The International Multiple Sclerosis Genetics Consortium

PLoS One. 2011 Apr 28;6(4).

Hedström AK, Sundqvist E, Bäärnhielm M, Nordin N, Hillert J, Kockum I, Olsson T, Alfredsson L. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.

Brain. 2011 Mar;134(Pt 3):653-64.

Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden.

Mult Scler. 2011 Aug;17(8):901-8.

2010

Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis.

Fertility and Sterility. 2010;94(7):2835-7

Rangsjö, Johansson, Ahlin, Landtblom, Österberg. Att använda SMSreg för riktad lokal analys av användningen av bromsmediciner (Lasarettet i Motala). Utsökning av par med hög EDSS och 0 skov under 2 år som underlag för seponering av dyrbara immunomodulerande bromsmediciner.

Accepterat abstract Kvalitetsregisterdagarna i Örebro 12-14 Okt 2010.

Burman J, Raininko R, Fagius J. Bilateral and recurrent opticneuritis in multiple sclerosis.

Acta Neurol Scand. 2014 Aug;130(2):81-9.

Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.

Mult Scler July 2010 vol. 16 no. 7 796-800

Karlberg E, Lundkvist M, Jungedal R, Hillert J, Fogdell-Hahn A. Formation of anti-natalizumab antibodies in natalizumab-treated multiple sclerosis patients.

Abstract, SSI Tallinn, Estonia, 2010, ECTRIMS Gothenburg 2010

Jungedal R, Lundkvist M, Karlberg E, Hillert J, Fogdell-Hahn A. Neutralizing Antibodies against IFN β – An Update from 2009.

Abstract, SSI Tallinn, Estonia, 2010, ECTRIMS Gothenburg 2010

Lundkvist M, Hillert J, Fogdell-Hahn A. Development of Neutralizing Antibodies against Interferon Beta does not Increase the Risk of Developing Antibodies against Natalizumab in Patients with Multiple Sclerosis.

Abstract, SSI Tallinn, Estonia, 2010, ECTRIMS Gothenburg 2010

Holmén C, Piehl F, Hillert J, Olsson T. The “Immunomodulation and Multiple Sclerosis Epidemiology” (IMSE) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri).

Abstract, ECTRIMS Gothenburg 2010

Kai-Larsen K, Nordin N, Hedström A, Hillert J, Olsson T, Alfredsson L. EIMS; an epidemiologic investigation of risk factors for multiple sclerosis.

Abstract, ECTRIMS Gothenburg 2010

Lycke K, Alfredsson L, Olsson T, Hillert J. From patient registry to Biobank - high participation in a nationwide survey of genes and environment in multiple sclerosis (GEMS study).

Abstract, ECTRIMS Gothenburg 2010

Salzer J, Svenningsson A, Sundström P. Season of Birth and Multiple Sclerosis in Sweden.

Acta Neurol Scand. 2010 Jul;122(1):70-3.

Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis.

Mult Scler. 2010 Mar;16(3):287-92.

Martola J, Bergström J, Fredrikson S, Stawiarz L, Hillert J, Zhang Y, Flodmark O, Lilja A, Ekbom A, Aspelin P, Kristoffersen Wiberg M. A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1 D, 2 D and volumetric measurements from MRI-images.

Neuroradiology. 2010 Feb;52(2):109-17

Carolina Havervall, Södertörns högskola/Institutionen för livsvetenskaper, CXCL13: A Prognostic Marker in Multiple Sclerosis.

Kandidatuppsats i biovetenskap på Karolinska Institutet 2010, handledare: Fredrik Piehl

2009

Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.

Neurology 2009 Sep 1;73(9):696-701.

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, Aspelin P, Kristoffersen Wiberg M. One-Dimensional-Ratio Measures of Atrophy Progression in Multiple Sclerosis as Evaluated by Longitudinal Magnetic Resonance Imaging.

Acta Radiol. 2009 Jul 28;1-9.

Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to cyclical hormone changes.

Eur J Contracept Reprod health Care 2009; 14(5):365-70.

Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents.

Neurology 2009 Mar 31;72(13):1170-7.

Holmén C, Piehl F, Hillert J, Olsson T. The "Immunomodulation and Multiple Sclerosis Epidemiology" (IMSE) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri).

Abstract, ECTRIMS in Düsseldorf 2009

Eva J. Greiner, Jan Hillert and the Swedish MS Registry. Effects of mitoxantrone treatment on different multiple sclerosis courses as documented in the Swedish multiple sclerosis registry.

Abstract, ECTRIMS in Düsseldorf 2009

Lundkvist M, Fogdell-Hahn A, Hillert J. Multiple sclerosis patients lacking antibodies in cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon-beta." publiceras i ett supplement till tidskriften

Abstract ECTRIMS 2009, publiceras i ett supplement till tidskriften Multiple Sclerosis september 2009

Karin Eliaeson, IVL, Marcus Liljeberg, IVL, Anders Björk, IVL, Ingrid Kockum, KI, Alasdair Skelton, SU, Eva-Jirner Lindström, SGU. Relationships of geochemistry and multiple sclerosis

IVL Svenska Miljöinstitutets rapport, B1824 December 2009

2008

Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM . Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.

Mult Scler. 2008 Nov;14(9):1208-13.

Flensner G, Ek AC, Landtblom AM, Söderhamn O. Fatigue in relation to perceived health: people with multiple sclerosis compared with people in the general population.

Scand J Caring Sci. 2008 Sep;22(3):391-400.

Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the Cost-Effectiveness of a New Treatment for MS (natalizumab) compared to Current Standard Practice in Sweden (An indirect comparison of a clinical trial with natalizumab with data from the Swedish MS Registry).

Multiple Sclerosis, 2008 Jun;14(5):679-9

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Aspelin P, Kristoffersen Wiberg M. Rate of ventricular enlargement in multiple sclerosis: a nine-year multiple resonance imaging follow-up study.

Acta Radiologica, 2008 Jun;49(5):570-9

Rikard Carlsson, apoteksstuderande, examensarbete: Evaluation of the first year of natalizumab treatment of MS: a retrospective study at the MS Center, Sahlgrenska University Hospital, Gothenburg.

Master Thesis in Pharmacy 2008, handledare Jan Lycke

Kristina Yilmaz, apoteksstuderande, examensarbete: Multiple sclerosis treatment with mitoxantrone: A retrospective study of patient selection, efficacy, and safety at the Department of Neurology, Sahlgrenska University Hospital.

Master Thesis in Pharmacy 2008, handledare Jan Lycke

Jenny Silversparre, apoteksstuderande, examensarbete: Treatment of multiple sclerosis with interferon beta: a retrospective study of the risk to develop neutralizing antibodies.

Master Thesis in Pharmacy 2008, handledare Jan Lycke

2007

Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Andersen O.

Att optimera historiska kontroller. Utvärdering av långtidseffekter av MS-behandling med "virtual placebo". En studie av MS naturalförlopp.

Läkartidningen. 2007 May 30-Jun 3;104(22):1684-8

Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, Spurkland A, Lie BA, Palmgren J, Celius EG, Hillert J, Harbo HF. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients.
Eur J Neurol. 2007 Aug;14(8):835-40.

Lundmark F, Salter H, Hillert J. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis.
Mult Scler. 2007 Jul;13(6):697-700

Nilsagård Y, Fedeli C, Gunnarsson L-G, Denison E. Clinical relevance using timed walk tests and 'timed up and go' testing in persons with Multiple Sclerosis. Reproducibility, correlations, and smallest percentage to detect genuine change.
Physiotherapy Research International 2007;12(2): 105-114.

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Kristoffersen-Wiberg M. Progression of non-age related callosal brain atrophy in multiple sclerosis. A nine years longitudinal MRI study representing four decades of disease development.
J Neurol Neurosurg Psychiatry. 2007 Apr; 78(4):375-80.

Nilsagård Y, Gunnarsson L-G, Deinson E. Self-perceived limitations of gait in persons with Multiple Sclerosis.
Advances in Physiotherapy 2007; 9(3):136-143.

2006

Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct.
Neurology (2006) 67:1062-4.

Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure.
Maturitas. 2006 May 20;54(2):149-53.

Nilsagård Y, Denison E, Gunnarsson L-G. Evaluation of a single session with cooling garment for persons with multiple sclerosis - a randomized trial.
Disability and Rehabilitation 2006;1(4):225-233.

2005

Flensner G., Ek A-C., Söderhamn O. Reliability and validity of the Swedish version of the Fatigue Impact scale (FIS).
Scandinavian Journal of Occupational Therapy, 2005, 12: 170-180.

Flensner G. Fatigue in individuals with Multiple Sclerosis. Lived experiences and perceived impact in daily life. Linköping University, Medical Dissertation No 917, Department of Medicine and Care, Division of Nursing Science, Faculty of Health Sciences, Linköping University, 2005.

En beskrivning av SMS-registret finns i den nya upplagan av "Multipel skleros - Metodpärm" som tryckts i en första upplaga på ett par hundra exemplar och som nu 2005 finns tillgänglig på Svenska MS-Sällskapets hemsida.

2004

Landtblom AM, Flensner G, Callander M, Stawiarz L. The Swedish MS registry points out an important clinical problem: physical and psychological fatigue is a main symptom in multiple sclerosis.
Läkartidningen. 2004 Oct 28; 101(44):3456-7.

Inger Boström, sjuksköterska, Kristinehamn "Är Värmland ett högriskområde för multipel skleros?".
Magisterarbete som lagts fram 20 Sept. 2004, Nordiska Vårdhögskolan, Göteborg. Handledare AM Landtblom, Max Petzold.

Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, Hafler DA, Kuchroo VK, Olsson T, Piehl F, Wallström E. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.

J Immunol. 2004 Jun 1;172(11):7169-76.

Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis.

J Immunol. 2004 Jan 1;172(1):661-8.

2003

Data ur SMS-registret diskuterades i två debattartiklar i läkartidningen våren 2003 av Jan Fagius respektive Jan Hillert. "Sjukdomsmodifierande behandling mot MS - framsteg med komplikationer" (jämte)

Replik: "Problemet är underbehandlingen!" av Jan Hillert (deb) 2003 nr 13 sid 1164-8.

Maria Turesson, med. kand., uppsats "Evidens-baserad Interferon-behandling i teori och praktik".

Redovisades den 2/6 2003 (SMS-registret var delvis använt för att undersöka hur neurolog mottagning i Lund följer Läkemedelsverkets rekommendationer för interferon-behandling).

Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients.

Scand J Immunol. 2003 May;57(5):493-7.

Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis.

J Neuroimmunol. 2003 Mar; 136(1-2):112-8.